InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: PaPaGriz post# 3324

Saturday, 06/09/2018 7:22:39 PM

Saturday, June 09, 2018 7:22:39 PM

Post# of 3833
Another source citing BMY’s interest in NASH.

“Buying has perked up in certain stocks with exposure to non-alcoholic steatohepatitis (NASH) after Bristol-Myers Squibb's (BMY +0.8%) business development chief Paul Biondi said that the company is ‘actively looking for acquisitions or license opportunities’ in fibrotic diseases (per DealReporter).” - Douglas House

"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News